Clinical trial · people
Setmelanotide: patients reported less hunger, more energy in TRANSCEND
Checked against the paper Clinical trialPublished by PepVault
The takeaway
For acquired hypothalamic obesity, this study adds patient and caregiver accounts that the benefits people noticed on setmelanotide went beyond weight, to hunger, energy and activity.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 30
- Published
- 2026
- Journal
- Front Behav Neurosci
What they tested
The team wanted to learn how people with acquired hypothalamic obesity, and their caregivers, experienced changes in hunger, weight, energy and activity on setmelanotide, and whether those changes mattered to them.
How the study was done
An interview substudy of the Phase 3 TRANSCEND trial, which was randomized, double-blind and placebo-controlled (placebo, a dummy treatment). Researchers held 75-minute guided interviews with 30 US trial participants or their caregivers between July 2024 and January 2025, then sorted what people said into common themes.

Model. Individual results vary.
What they found
The 30 people interviewed included 16 caregivers and 14 people enrolled in the trial, 10 of them adults and 4 of them teens; setmelanotide was the treatment in 23 cases and placebo in 7. Looking back to the time after their hypothalamic injury and before the trial, every interviewee described hunger that was never satisfied and weight that kept climbing fast, and 29 of 30 described low energy. Those on setmelanotide, and the caregivers of those on it, described gains in hunger, weight, energy and physical activity, and said these gains were meaningful to them. Interviewees from the placebo group described no such changes.
What it doesn’t show
This was a small interview study of English-speaking US participants, with only 7 on placebo, and it captured what people said rather than measured outcomes. It is a substudy of a larger trial, so it adds personal accounts rather than new measurements.
The paper
Roth et al. Quality of life improvements with setmelanotide treatment in acquired hypothalamic obesity: TRANSCEND trial interview results from US participants. Front Behav Neurosci. 2026.
The compound
More studies on Setmelanotide
- Setmelanotide: injection-site reactions in 96% in pooled trialsMeta-analysis · people · 2026
- Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesityRandomized trial · people · 2026
- Setmelanotide: mean BMI fell 18% at 52 weeks in ages 2-5 (VENTURE)Clinical trial · people · 2025
- Setmelanotide: 15% mean BMI drop at 16 weeks in hypothalamic obesityClinical trial · people · 2024
- Setmelanotide: quality of life rose after 52 weeks in Bardet-BiedlClinical trial · people · 2023
- Setmelanotide: 80% (POMC) and 45% (LEPR) lost at least 10% weightClinical trial · people · 2020
- Every study on Setmelanotide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.